{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:07:20Z","timestamp":1775146040301,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["KRYC-YQ-2116"],"award-info":[{"award-number":["KRYC-YQ-2116"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chemo-immunotherapy has become the best first-line treatment for advanced lung cancer patients without oncogenic drivers. However, it may also lead to an increased incidence and severity of treatment-related adverse events. In this retrospective study, lung cancer patients administrated with either anti-PD-1 or anti-PD-L1 treatment plus chemotherapy were included. Data on demographic characteristics, disease characteristics, treatment strategies, laboratory results, and clinical outcomes were collected from the Electronic Medical Records System and evaluation scales. Chi-square, univariate, and multivariate logistic regression analyses were used to identify the risk factors for immune-related adverse events (irAEs). A total of 116 patients were included in the study, and the majority experienced treatment-related adverse events. Adverse events of any grade were reported in 114 (98.3%) patients, with 73 (62.9%) experiencing Grade 3 or higher events. The most frequent adverse events were anemia (67.2%), decreased appetite (62.9%), and alopecia (53.4%). Fifty-four (46.6%) patients were diagnosed with irAEs, with hypothyroidism (28.4%) being the most commonly reported. Multivariable analysis demonstrated a significant correlation between the number of treatment cycles, elevated baseline levels of thyroid stimulating hormone (TSH) and interleukin-6 (IL-6) with irAEs (OR\u2005=\u20051.222, P\u2005=\u20050.009, OR\u2005=\u20051.945, P\u2005=\u20050.016, OR\u2005=\u20051.176, P\u2005=\u20050.004), and IL-6 was identified as a strong predictor of severe irAEs (OR\u2005=\u20051.084, P\u2005=\u20050.014). Our study demonstrated the safety of chemo-immunotherapy in lung cancer patients without additional toxicity. The number of treatment cycles, higher baseline levels of TSH and IL-6 were identified as potential clinical biomarkers for irAEs.<\/jats:p>","DOI":"10.1093\/cei\/uxad105","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T23:17:15Z","timestamp":1694474235000},"page":"162-169","source":"Crossref","is-referenced-by-count":7,"title":["Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer"],"prefix":"10.1093","volume":"214","author":[{"given":"Jinjin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"},{"name":"Chongqing Clinical Research Center for Geriatrics and Gerontology , Chongqing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9563-9568","authenticated-orcid":false,"given":"Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital, Chongqing Medical University , Chongqing , China"},{"name":"Guchengtai Community Health Center of Chengxi District , Xining , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"2023121223013459200_CIT0001","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2023121223013459200_CIT0002","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2023121223013459200_CIT0003","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121223013459200_CIT0004","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023121223013459200_CIT0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"2023121223013459200_CIT0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non\u2013small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"2023121223013459200_CIT0007","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023121223013459200_CIT0008","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"2023121223013459200_CIT0009","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2023121223013459200_CIT0010","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2023121223013459200_CIT0011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2023121223013459200_CIT0012","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2023121223013459200_CIT0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials","volume":"63","author":"Zhang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"2023121223013459200_CIT0014","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2023121223013459200_CIT0015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023121223013459200_CIT0016","doi-asserted-by":"crossref","first-page":"585311","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events\u2014a comprehensive review","volume":"10","author":"Hommes","year":"2021","journal-title":"Front Oncol"},{"key":"2023121223013459200_CIT0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2023121223013459200_CIT0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023121223013459200_CIT0019","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2023121223013459200_CIT0020","doi-asserted-by":"crossref","first-page":"175883592110185","DOI":"10.1177\/17588359211018537","article-title":"Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis","volume":"13","author":"Sheng","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2023121223013459200_CIT0021","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cncr.33270","article-title":"Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: a meta-analysis of randomized control trials","volume":"127","author":"Wang","year":"2021","journal-title":"Cancer"},{"key":"2023121223013459200_CIT0022","doi-asserted-by":"crossref","first-page":"974376","DOI":"10.3389\/fphar.2022.974376","article-title":"PD-1 inhibitor-based adverse events in solid tumors: a retrospective real-world study","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023121223013459200_CIT0023","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2023121223013459200_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III Non-small cell lung cancer: the phase 2 KEYNOTE-799 Nonrandomized Trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"2023121223013459200_CIT0025","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2023121223013459200_CIT0026","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"2023121223013459200_CIT0027","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2023121223013459200_CIT0028","doi-asserted-by":"crossref","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023121223013459200_CIT0029","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"2023121223013459200_CIT0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"2023121223013459200_CIT0031","doi-asserted-by":"crossref","first-page":"e000678","DOI":"10.1136\/jitc-2020-000678","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2023121223013459200_CIT0032","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"2023121223013459200_CIT0033","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"2023121223013459200_CIT0034","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"2023121223013459200_CIT0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","article-title":"IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets","volume":"41","author":"Unver","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023121223013459200_CIT0036","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","article-title":"Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"2023121223013459200_CIT0037","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cod.14038","article-title":"Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma","volume":"86","author":"Peng","year":"2022","journal-title":"Contact Dermatitis"},{"key":"2023121223013459200_CIT0038","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non\u2013small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023121223013459200_CIT0039","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2023121223013459200_CIT0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"key":"2023121223013459200_CIT0041","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1053\/j.seminhematol.2013.03.015","article-title":"Autoimmunity and novel therapies in immune-mediated thrombocytopenia","volume":"50","author":"Yehudai","year":"2013","journal-title":"Semin Hematol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxad105\/51798786\/uxad105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/2\/162\/54329531\/uxad105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/214\/2\/162\/54329531\/uxad105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:02:11Z","timestamp":1702422131000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/214\/2\/162\/7269097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,11]]},"published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxad105","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,9,11]]}}}